Keywords: UK, NICE, Eli Lilly, Alimta, NSCLC, Pemetrexed, Lung cancer
Data uncertainties mean NICE unable to recommend pemetrexed for NSCLC maintenance treatment
Article | 17 December 2009
Giving an initial negative opinion, the UK’s National Institute for Health and Clinical Excellence (NICE) is currently appraising the use of pemetrexed (brand name Alimta, a chemotherapy drug manufactured and marketed by US drug major Eli Lilly, which is indicated for the treatment of pleural mesothelioma as well as non-small cell lung cancer) for the maintenance treatment of non-small-cell lung cancer.
In its draft guidance, published today, the NICE does not recommend pemetrexed. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
